Cutler Group LP Arcus Biosciences, Inc. Call Options Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Jan 18, 2024	BUY	$13.43 - $19.63 $9,401 - $13,741	700 Added 53.85%	2,000 $9,000
Q3 2023 Nov 07, 2023	BUY	$17.62 - $23.54 $22,906 - $30,602	1,300 New	1,300 $0
Q3 2022 Oct 25, 2022	BUY	$23.23 - $30.07 $46,460 - $60,140	2,000 Added 1000.0%	2,200 $3,000
Q2 2022 Aug 04, 2022	SELL	$17.23 - $37.73 $27,568 - $60,367	-1,600 Reduced 88.89%	200 $0
Q1 2022 Apr 14, 2022	BUY	$28.92 - $41.83 $23,136 - $33,464	800 Added 80.0%	1,800 $4,000
Q4 2021 Jan 18, 2022	BUY	$31.38 - $48.47 $31,380 - $48,470	1,000 New	1,000 $3,000
Q3 2020 Oct 27, 2020	SELL	$17.14 - $25.47 $85,700 - $127,350	-5,000 Closed	0 $0
Q2 2020 Jul 22, 2020	BUY	$13.97 - $36.56 $69,850 - $182,800	5,000 New	5,000 $0

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.12B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.